At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 407 enrolled
Drug / intervention
CTP-543drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
In Brief
A Phase 3 clinical trial evaluating CTP-543 for Alopecia Areata. Completed, enrolled 407 participants across 39 sites in 5 countries.
Detailed Summary
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata. Patients from European sites who previously completed a qualifying CTP-543 clinical trial may participate in this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesFrance, Germany, Hungary, Poland, Spain
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartOct 2021
Primary CompletionJul 2024
TodayJul 2026
First PostedSep 13, 2021
Enrollment StartOct 19, 2021
Primary CompletionJul 18, 2024
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 4.8 years ago
Interventions
CTP-543drug
Twice daily dosing